Abeona Therapeutics (NASDAQ:ABEO) Upgraded by StockNews.com to “Hold” Rating

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a report issued on Wednesday.

A number of other research analysts have also recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Thursday, October 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a research note on Tuesday, October 29th.

Abeona Therapeutics Trading Down 2.4 %

Shares of Abeona Therapeutics stock opened at $5.75 on Wednesday. The stock has a fifty day moving average price of $6.19 and a 200-day moving average price of $5.27. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The firm has a market cap of $249.95 million, a PE ratio of -2.14 and a beta of 1.52. Abeona Therapeutics has a 1 year low of $3.05 and a 1 year high of $9.01.

Institutional Investors Weigh In On Abeona Therapeutics

Several institutional investors have recently made changes to their positions in the stock. abrdn plc lifted its holdings in Abeona Therapeutics by 158.8% during the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock worth $2,067,000 after purchasing an additional 200,647 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after buying an additional 429,456 shares in the last quarter. Simplify Asset Management Inc. bought a new position in shares of Abeona Therapeutics in the second quarter valued at approximately $1,732,000. Acadian Asset Management LLC purchased a new position in Abeona Therapeutics during the first quarter valued at approximately $91,000. Finally, Rosalind Advisors Inc. increased its holdings in Abeona Therapeutics by 4.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after acquiring an additional 82,000 shares during the period. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.